Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe.

Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.

She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). Dr. Torley is a member of the board of directors for Quest Diagnostics. She is also a member of the Health Section Governing Board of BIO, the Biotechnology Innovation Organization, and chair of BIO’s Workforce Development, Diversity and Inclusion committee.

Laurie D. Stelzer , , , Senior Vice President & Chief Financial Officer

Ms. Stelzer brings to Halozyme an extensive finance and business background. Leading teams in Finance, Treasury, Investor Relations, Business Development and Emerging Markets. Ms. Stelzer joined Halozyme in June 2015 as Senior Vice President, Chief Financial Officer. She is responsible for the Finance, Information Technology, Facilities and Site Operations organizations.

Prior to Halozyme, Ms. Stelzer served as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc. Prior to that she was the Division CFO for the Regenerative Medicine Division and the Head of Investor Relations at Shire. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc., including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries.

Ms. Stelzer received her B.S. in Accounting from Arizona State University and her MBA from the Anderson School at the University of California, Los Angeles. She is a member of the board of directors for Surface Oncology.

Michael J. LaBarre , , Ph.D. , , Senior Vice President, Chief Technical Officer

Dr. LaBarre brings to Halozyme more than 25 years of experience across all aspects of biopharmaceutical research and drug development, including strong expertise in chemistry, manufacturing, and controls (CMC), regulatory strategy and product development. Dr. LaBarre joined Halozyme in 2008 and has held leadership positions in product development, alliance management, research, and regulatory affairs during that time. He is currently responsible for providing scientific and technical leadership across all Halozyme programs and is the lead expert on Halozyme’s ENHANZE® drug delivery technology.

Prior to Halozyme, Dr. LaBarre served as Vice President of Product Development at Paramount BioSciences, LLC, where he led CMC and research efforts for the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served from 1995 to 2006 in various research and development positions at Biogen Idec (formerly IDEC before the merger with Biogen in 2004), where he supported numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. and he began his career at Hybritech in San Diego in 1992. Dr. LaBarre also taught chemistry laboratory for several years as an adjunct professor at Mesa Community College early in his career.

Dr. LaBarre received his B.S. in Chemistry from Southampton College of Long Island University and his Ph.D. in Chemistry from the University of Arizona.

Mas Matsuda , , Esq. , , Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Mr. Matsuda brings to Halozyme 20 years of corporate legal experience in the global life sciences industry. He brings corporate law, compliance, commercial law, employment and mergers and acquisitions experience, with extensive experience in the biotechnology space. Mr. Matsuda joined Halozyme in August 2018 as Vice President, Associate General Counsel and Chief Compliance Officer.  Prior to Halozyme, he served as Vice President, Law, Global Commercial Operations at Amgen, primarily responsible for strategic commercial legal support to the U.S. Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing and Biosimilars division. Throughout his 18-year career at Amgen, he held roles of increasing responsibility, including regional general counsel for the Latin America, Canada, Australia and New Zealand region, lead counsel to the European commercial operations, employment and tax groups, and lead counsel to each of the U.S. Value & Access Business Unit, Inflammation Business Unit and Nephrology Business Unit. Prior to Amgen, Mr. Matsuda worked in private practice at the law firms of Pillsbury Winthrop Shaw Pittman LLC and Orrick Herrington & Sutcliffe LLP in their respective company practice and corporate securities groups.

Mr. Matsuda received his B.S. in Business Administration with a dual emphasis in Corporate Finance and International Finance from the University of Southern California, and his J.D. from University of California, Hastings College of the Law.

Al Kildani , , , Vice President of Investor Relations and Corporate Communications

Mr. Kildani brings to Halozyme a unique perspective based on his diverse experience from both the financial and life sciences industries. Mr. Kildani joined Halozyme in November 2018 as Vice President of Investor Relations and Corporate Communications. He is responsible for developing and executing Halozyme’s investor relations strategy and serves as the primary contact for analysts and the investment community. Additionally, he oversees all aspects of corporate communications, including public relations and external and internal communications.

Prior to Halozyme, Mr. Kildani served as Vice President, Investor Relations and Business Development for Vital Therapies, Inc., where he was responsible for the overall strategy and external messaging to institutional investors and performed due diligence on potential business development opportunities. He previously held senior investor relations and corporate communications roles at Hologic, Inc. and Gen-Probe, Inc. Prior to these roles, Mr. Kildani spent over 12 years in the securities industry with a focus on life sciences companies. He was an analyst with Stark Investments, C.E. Unterberg, Towbin, and Pacific Growth Equities LLC.

Mr. Kildani received his B.S. in Business Administration from Boston College, and is a member of the National Investor Relations Institute (NIRI).


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.